What happened in the latest QGEN analyst rating?

On February 05, 2026 Jefferies maintained a Buy on Qiagen N.V. (QGEN) and raised its price target to $59. The action reaffirmed confidence and produced a 1.33% intraday price move.

Does the QGEN price target change mean a full upgrade?

No. Jefferies maintained its Buy rating while raising the target from $57 to $59. That is a target tweak, not an upgrade from a lower rating category.

How should investors use this QGEN analyst rating?

Treat the maintained Buy and higher target as positive confirmation. Combine it with financials, upcoming earnings, and Meyka AI analysis before adjusting positions.

Where can I read the original analyst note?

The price target change was reported by TheFly on February 05, 2026. Jefferies’ specifics can be reviewed through that report and recent earnings coverage on Seeking Alpha.

Analyst Ratings

Jefferies Maintains Buy on Qiagen N.V. (QGEN) Feb 2026

ByHuzaifa Zahoor February 6, 2026February 6, 2026

Jefferies maintained a Buy on Qiagen N.V. (QGEN) and raised its price target to $59 on February 05, 2026. This QGEN analyst rating action came at 03:44 PM and accompanied a 1.33% ($0.68) intraday price move. The firm left its underlying Buy conviction unchanged while nudging the price target higher from $57. Investors should view this as a reaffirmation of Jefferies’ view on demand for molecular diagnostics and recurring revenue streams. Meyka AI rates QGEN with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.